Novel intravascular tantalum oxide-based contrast agent achieves improved vascular contrast enhancement and conspicuity compared to Iopamidol in an animal multiphase CT protocol

Autor: Maurice M. Heimer, Yuxin Sun, Sergio Grosu, Clemens C. Cyran, Peter J. Bonitatibus, Nikki Okwelogu, Brian C. Bales, Dan E. Meyer, Benjamin M. Yeh
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: European Radiology Experimental, Vol 8, Iss 1, Pp 1-10 (2024)
Druh dokumentu: article
ISSN: 2509-9280
55265421
DOI: 10.1186/s41747-024-00509-2
Popis: Abstract Background To assess thoracic vascular computed tomography (CT) contrast enhancement of a novel intravenous tantalum oxide nanoparticle contrast agent (carboxybetaine zwitterionic tantalum oxide, TaCZ) compared to a conventional iodinated contrast agent (Iopamidol) in a rabbit multiphase protocol. Methods Five rabbits were scanned inside a human-torso-sized encasement on a clinical CT system at various scan delays after intravenous injection of 540 mg element (Ta or I) per kg of bodyweight of TaCZ or Iopamidol. Net contrast enhancement of various arteries and veins, as well as image noise, were measured. Randomized scan series were reviewed by three independent readers on a clinical workstation and assessed for vascular conspicuity and image artifacts on 5-point Likert scales. Results Overall, net vascular contrast enhancement achieved with TaCZ was superior to Iopamidol (p ≤ 0.036 with the exception of the inferior vena cava at 6 s (p = 0.131). Vascular contrast enhancement achieved with TaCZ at delays of 6 s, 40 s, and 75 s was superior to optimum achieved Iopamidol contrast enhancement at 6 s (p ≤ 0.036. Vascular conspicuity was higher for TaCZ in 269 of 300 (89.7%) arterial and 269 of 300 (89.7%) venous vessel assessments, respectively (p ≤ 0.005), with substantial inter-reader reliability (κ = 0.61; p
Databáze: Directory of Open Access Journals
Externí odkaz: